Europe – Industry calls for IP protection, innovation support in EC pharmaceutical roadmap

The European Commission (EC) has posted feedback it received on a new roadmap for a pharmaceutical strategy aimed at increasing timely patient access to affordable medicines. The feedback period began 16 June; a period of public consultation remains open until 15 September, with commission adoption planned for the 4th quarter of 2020.

Organizations leaving feedback generally welcomed the development of the roadmap, but many pharmaceutical manufacturers and trade associations expressed concern that innovation and global competitiveness would not be adequately boosted. The European Federation of Pharmaceutical Industries and Associations (EFPIA) left feedback critiquing the roadmap for lacking “the necessary drivers of innovation to realize its own ambition of supporting the industry in Europe to be a world leader in innovation.” (RELATED: European Commission consults on roadmap to pharmaceutical reforms, Regulatory Focus 02 June 2020)
A more robust intellectual property framework is needed for the EU to be “at the forefront of pharmaceutical innovation,” said EFPIA, which also called for a strengthened research and manufacturing infrastructure. “That means developing clinical trial networks, biobanks and data banks, building a European health data space, delivering public-private collaboration mechanisms to accelerate bringing health solutions to patients and encouraging innovative manufacturing,” said the association, which also called for a stable, adaptable, fast and globally effective regulatory framework with speedier approval times…